B of A Securities Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6
Lyell Immunopharma Analyst Ratings
Bank of America Securities Keeps Their Buy Rating on Lyell Immunopharma (LYEL)
Lyell Immunopharma Analyst Ratings
HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6
Lyell Immunopharma Analyst Ratings
HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $8
Lyell Immunopharma Analyst Ratings
Promising Financial and Clinical Prospects: A Comprehensive Buy Rating Analysis for Lyell Immunopharma
JP Morgan Cuts Lyell to Neutral, Pending Data for Cell Therapy Platform
JP Morgan Downgrades Lyell Immunopharma to Neutral, Lowers Price Target to $5
Lyell Immunopharma Analyst Ratings
H.C. Wainwright Reaffirms Their Buy Rating on Lyell Immunopharma (LYEL)
HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $9 Price Target
Lyell Immunopharma (LYEL) Receives a Buy From H.C. Wainwright
HC Wainwright Adjusts Price Target on Lyell Immunopharma to $9 From $11, Maintains Buy Rating
Morgan Stanley Adjusts Lyell Immunopharma's Price Target to $4 From $7, Maintains Equal Weight Rating
Morgan Stanley Sticks to Its Hold Rating for Lyell Immunopharma (LYEL)
Lyell Immunopharma Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Lyell Immunopharma, Lowers Price Target to $4
No Data